Trial Profile
A randomized, multicenter, double-blind, parallel-group, placebo-controlled, pilot trial of omalizumab, in patients with severe allergic asthma requiring daily treatment with high-dose ICS, with or without oral corticosteroids.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Sep 2015
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Allergic asthma
- Focus Therapeutic Use
- 05 Nov 2010 New trial record.